+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Phospholipid Analysis of Mammalian Optic Nerve Tissue: A 31P Nuclear Magnetic Resonance Spectroscopic Study

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Phospholipids of optic nerve (n = 30) from 5.6-kg rabbits were analyzed by <sup>31</sup>P nuclear magnetic resonance (NMR) spectroscopy. Phospholipid metabolites detected were as follows (mol %): phosphatidylcholine (PC; 25.82 ± 0.12), PCplasmalogen/ alkylacyl PC (2.07 ± 0.13), sphingosylphosphorylcholme (1.12 ± 0.20), phosphatidylinositol (PI; 2.17 ± 0.21), lysoPC (0.85 ± 0.06), sphingomyelin (12.52 ± 0.10); phosphatidyl-serine(PS; 14.38 ± 0.11), phosphatidylethanolamine(8.98 ± 0.11), ethanolamine plasmalogen (28.99 ± 0.30), unidentified phospholipid (1.10 ± 0.01), phosphatidic acid (PA; 1.72 ± 0.06), and lyso PS (0.28 ± 0.10). The bulk of the ethanolamine phosphatide is in the form of its plasmalogen, which is the major phospholipid detected. The choline plasmalogen, or a reduced derivative thereof, also is present; thus, a significant phospholipid biosynthetic pathway for optic nerve tissue involves the plasmalogen route, which is a pathway distinct from the PA route responsible for the synthesis of PS, PI, and PC. This new <sup>31</sup>P NMR lipid analytical technique offers potential for studying optic nerve phospholipid metabolism and degenerating optic nerve tissue, since the technique can accurately quantitate (1) both plasmalogen and nonplasmalogen phospholipids, (2) minor phospholipid components, and (3) previously undetected phospholipids.

          Related collections

          Author and article information

          Ophthalmic Res
          Ophthalmic Research
          S. Karger AG
          11 December 2009
          : 26
          : 5
          : 264-274
          aSchepens Eye Research Institute and bDepartment of Ophthalmology, Harvard Medical School, Boston, Mass., and cMagnetic Resonance Laboratory, Midwestern University, Chicago, Ill., USA
          267488 Ophthalmic Res 1994;26:264–274
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Original Paper


          Comment on this article